Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 6/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670243 | 0.85 | KCNK3 (0.39) | TP53KCNK3LMNAMAPTSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29670442 | 0.83 | CDC7 (0.34) | TP53KCNK3 | |
| SCHEMBL22845402 | 0.82 | P2RX3 (0.43) | P2RX3KDM1ATP53MAPT | |
| SCHEMBL24470065 | 0.81 | P2RX3 (0.41) | P2RX3TP53MAPT | |
| SCHEMBL24484016 | 0.81 | P2RX3 (0.36) | P2RX3KDM1ATP53MAPT | |
| SCHEMBL24469837 | 0.79 | P2RX3 (0.41) | P2RX3TP53LMNAMAPTSMN1; SMN2 | |
| SCHEMBL24484081 | 0.76 | PDE6D (0.36) | TP53PDE10AMAPT | |
| SCHEMBL22845225 | 0.75 | MAPT (0.46) | P2RX3KDM1ATP53PDE10AMAPT | |
| SCHEMBL22845209 | 0.74 | MAPT (0.42) | TP53KCNK3LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22717340 | 0.74 | P2RX3 (0.41) | P2RX3KDM1ATP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |